Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202717 | 0.84 | PIM1 (0.46) | PLK4AURKADAPK3CHEK2CDK1 | |
| SCHEMBL4592815 | 0.70 | GPR35 (0.42) | GPR35BCL2L1PLK4AURKADAPK3 | |
| SCHEMBL1310113 | 0.70 | GPR35 (0.68) | GPR35BCL2L1PLK4AURKADAPK3 | |
| SCHEMBL31081263 | 0.69 | CCNE1 (0.43) | GPR35AURKACDK1CDK2KDM4E | |
| Hydrochloric Acid SCHEMBL5981436 | 0.69 | GPR35 (0.41) | GPR35BCL2L1PLK4AURKADAPK3 | |
| SCHEMBL28531853 | 0.68 | GPR35 (0.65) | GPR35BCL2L1PLK4AURKADAPK3 | |
| SCHEMBL27929319 | 0.68 | CYP2A6 (0.43) | ICAM1SELE | |
| SCHEMBL1244927 | 0.68 | GPR35 (0.47) | GPR35BCL2L1PLK4AURKADAPK3 | |
| SCHEMBL1622149 | 0.68 | CYP2A6 (0.40) | AURKADAPK3PIM1MAPK9GSK3A | |
| SCHEMBL10769399 | 0.67 | GPR35 (0.38) | GPR35BCL2L1CSNK2A1DAOKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-02-13 | — | — | US | disclosed |
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3795573-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRIDINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Hutchison Medipharma Limited (CN) | 2021-03-24 | — | — | EP | disclosed |
| US-10946014-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-03-16 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1534716-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004007504-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GPR35 755/4885BCL2L1 1353/4885PLK4 3598/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | GPR35 755/4885BCL2L1 1353/4885PLK4 3598/4885 |
| US-10946014-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | KCNJ11, NISCH, CYP4Z1 | GPR35 1654/4885BCL2L1 4313/4885PLK4 1610/4885 |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | GPR35 1654/4885BCL2L1 4313/4885PLK4 1610/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GPR35 762/4885BCL2L1 1362/4885PLK4 3599/4885 |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | TK2, TYMP, DPYD | GPR35 1993/4885BCL2L1 2669/4885PLK4 631/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | GPR35 1654/4885BCL2L1 4313/4885PLK4 1610/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GPR35 752/4885BCL2L1 1306/4885PLK4 3595/4885 |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | GPR35 1654/4885BCL2L1 4313/4885PLK4 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.